No supplier or customer ties in DMRA's filings yet. The map draws only what companies disclose to the SEC; ties named in other companies' filings join as the graph reads them.
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.
Nothing on the wire mentions DMRA yet. Iris sweeps the public feeds every quarter hour; headlines land here the moment a sweep tags them.
How DMRA has moved on past release days vs its typical ±5.1% day, and how often it closed up. Computed from daily closes — not a forecast.